表皮生长因子受体酪氨酸激酶抑制剂相关皮疹的中西医治疗进展

Progress on Treatment of EGFR-TKI-related Skin Rash with Traditional Chinese Medicine and Western Medicine

表皮生长因子受体酪氨酸激酶抑制剂(epidermal growth factor receptor-tyrosine kinaseinhibitor,EGFR-TKI)为EGFR敏感突变非小细胞肺癌(non-small cell lung cancer,NSCLC)患者一线治疗方案。近年来多项研究证实,EGFR-TKI最常见的不良反应是其相关性皮疹,严重者可能影响EGFR-TKI的使用。现代医学主要从对角质形成细胞和皮脂腺的作用、炎性反应及皮肤损伤等方面进行研究。中医将其归为"药毒"范畴并进行辨证论治。全文结合相关文献对EGFR-TKI相关皮疹的发生及中西医治疗作一综述。

Epidermal growth factor receptor-tyrosine kinase inhibitor(EGFR-TKI) is a first-line treatment for patients with EGFR-sensitive non-small cell lung cancer(NSCLC). Skin rash is the most common adverse reaction of EGFR-TKI,which may affect the use of EGFR-TKI in severe cases. Modern medicine revealed that the pathogenesis of EGFR-TKI-related rash is associated with the effects of keratinocytes and sebaceous glands,inflammatory reactions and skin damage.Traditional Chinese medicine classifies it as 'drug-toxic' and applies syndrome differentiation and treatment. This article reviews the pathogenesis of EGFR-TKI-related rash and its treatment with Chinese and Western medicine.